Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

Publication | Closed Access

DOI

Citations

References

2019

Year

Johannes Weller, Theophilos Tzaridis, Frederic Mack, Joachim P. Steinbach, Uwe Schlegel, Peter Hau, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Oliver Bähr,

The Lancet Oncology

Neuro-oncologyTreatment StrategiesNeurological AssessmentCognitive PerformanceHealth-related QualityMedicineNeurocognitive FunctioningClinical NeurologyRehabilitationNeurologyHigh-grade GliomasBrain LesionLomustine–temozolomide Versus TemozolomideOncologyGliomaGlioblastomaHealth Sciences